Congress boosts brain stimulation research for veterans, with Nexalin involved

2026-03-09 11:40:05

Abstract generation in progress

Nexalin Technology (NXL) lauded recent Congressional actions that increase federal backing for deep brain neurostimulation research, stating its DIFS™ technology aligns with VA and NIH priorities. The company highlighted two appropriations reports signed into law supporting neuromodulation research and an ongoing study with UC San Diego/San Diego VA using DIFS™. While H.R. 7091 is still under committee review, Nexalin sees these legislative moves as a significant step toward recognizing neurostimulation as a high-potential therapeutic approach for conditions like TBI, PTSD, and Alzheimer’s.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.